Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug discontinuation study: safety first

NCT ID NCT07214285

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows one Parkinson's patient who has been receiving A-dopamine directly into the brain via a pump for years. The goal is to monitor safety during long-term use and manage a gradual, individualized dose reduction until the treatment stops, switching to an alternative like Scyova. It aims to prevent complications from abrupt discontinuation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A-dopamine (anaerobic dopamine) delivered via intracerebral pump
What this could lead to
If successful, this study could show that gradual dose reduction and switching to alternative treatments like Scyova is safe for Parkinson's patients.
What could go wrong
This is a very small follow-up study (only 1 participant) focused on safety, not effectiveness. The treatment is being discontinued, so it won't provide new evidence on long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

1 person

The number who actually took part.

Started

Oct 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients included in the DIVE I study still being treated with A-dopamine. * Social security beneficiary. * Able to give free and informed consent to participate in the research. * Patient willing to comply with all study procedures and duration. * Patient not planning to change their lifestyle (nutritionally, physically, and socially) during their participation in the study. Exclusion Criteria: * Patients not included in DIVE I and not treated with A-dopamine. * Presence of another serious condition that is life-threatening in the short or medium term, malnourished or cachectic patients. * Taking treatments containing guanethidine or its relatives, or non-selective and selective monoamine oxidase A inhibitors (iproniazid, moclobemide, toloxatone) * Patients already participating in another therapeutic trial involving the use of an experimental drug other than DIVE I or in an exclusion period * Isolated patients, defined as those without a caregiver present for at least 3 hours/day at the patient's home

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • UHLillle

    Lille, Haut de France, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.